echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > JCC: Analysis of the effectiveness and safety of Ustekinumab in ulcerative colitis

    JCC: Analysis of the effectiveness and safety of Ustekinumab in ulcerative colitis

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Inflammatory bowel disease (IBD), including Crohn's disease (CD) and medsci.


    Inflammatory bowel disease (IBD), including Crohn's disease (CD) and medsci.


    Although traditional treatment drugs can improve symptoms, they cannot prevent the underlying inflammatory process.


    immunity

    UTI slave monoclonal antibody (Ustekinumab) is the world's first fully human "dual targeting" IL-12 and IL-23 inhibitor, received US Food and Drug Administration as early as in 2008 Management Board ( the FDA ) approved for the treatment of psoriasis It was approved for the treatment of active CD in 2016, and the CD indication was approved in China in March 2020.


    Manage FDA

     

     

    The researchers prospectively included patients in the ENEIDA registry into this study.


     

    A total of 95 patients were included in this study.


    Figure: Changes in the efficacy of Ulsinumumab in the treatment of ulcerative colitis

     

    This study confirms that Ustekinumab has a good effect on alleviating disease activity in real life, both in the short and long term, but a higher burden of inflammation at baseline is associated with a lower probability of remission.


    This study confirms that Ustekinumab has a good effect on alleviating disease activity in real life, both in the short and long term, but a higher burden of inflammation at baseline is associated with a lower probability of remission.


     

    Original source:

    María Chaparro.


    oup.
    com/ecco-jcc/advance-article/doi/10.
    1093/ecco-jcc/jjab070/6228235" target="_blank" rel="noopener">Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.